Aytu BioPharma, Inc. (AYTU) Earnings History
Net Loss19 years of earnings data (2007–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Aytu BioPharma, Inc. (AYTU) Earnings Overview
As of June 22, 2026, Aytu BioPharma, Inc. (AYTU) reported trailing twelve-month net income of -$34M, reflecting +24.5% year-over-year growth. The company earned $-3.24 per diluted share over the past four quarters, with a net profit margin of -20.4%.
Looking at the long-term picture, AYTU's historical earnings data spans multiple years. The company achieved its highest annual net income of -$48,954 in fiscal 2007.
Aytu BioPharma, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SUPN (-$29M net income, -5.4% margin), TPVG (-$12M net income, 50.6% margin), ASRT (-$36M net income, -25.6% margin), AYTU has room to improve margins relative to the peer group. Compare AYTU vs SUPN →
AYTU Earnings vs Peers
Earnings metrics vs comparable public companies
AYTU Historical Earnings Data (2007–2025)
19 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$14M | +14.4% | -$8M | $-2.16 | -20.4% | -11.8% |
| 2024 | -$16M | +7.1% | -$2M | $-2.86 | -24.3% | -2.4% |
| 2023 | -$17M | +84.3% | -$17M | $-5.11 | -15.9% | -15.9% |
| 2022 | -$109M | -86.6% | -$110M | $-74.01 | -112.5% | -113.7% |
| 2021 | -$58M | -327.9% | -$59M | $-69.60 | -88.8% | -89.7% |
| 2020 | -$14M | +71.1% | -$21M | $-60.20 | -49.3% | -76.5% |
| 2019 | -$47M | -363.0% | -$17M | $-1210.28 | -644.3% | -230.1% |
| 2018 | -$10M | +54.7% | -$20M | $-3061.23 | -278.4% | -538.3% |
| 2017 | -$23M | +20.1% | -$20M | $-193194.38 | -698.7% | -624.7% |
| 2016 | -$28M | -264.9% | -$22M | $-999999.00 | -1099.7% | -847.0% |
| 2015 | -$8M | -38.4% | -$8M | $-551671.71 | -2950.3% | -2915.5% |
| 2014 | -$6M | -9632.9% | -$6M | $-619854.44 | -9466.8% | -10770.3% |
| 2013 | $-57,318 | +3.9% | $-52,414 | $-7164.75 | -3275.3% | -2995.1% |
| 2012 | $-59,675 | +56.4% | $-56,356 | $-7459.37 | -3410.0% | -3220.3% |
| 2011 | $-136,802 | -127.0% | $-133,619 | $-17100.25 | - | - |
| 2010 | $-60,270 | -2.3% | $-56,741 | $-10045.00 | - | - |
| 2009 | $-58,894 | -3.0% | $-55,822 | $-11778.80 | -3365.4% | -3189.8% |
| 2008 | $-57,173 | -16.8% | $-54,984 | $-11434.60 | - | - |
| 2007 | $-48,954 | - | $-46,890 | $-48954.00 | - | - |
Download Data
Export AYTU earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
19+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
AYTU — Frequently Asked Questions
Quick answers to the most common questions about buying AYTU stock.
What is AYTU earnings per share (EPS)?
AYTU trailing twelve-month (TTM) diluted EPS is $-3.24, reflecting +24.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2007 to 2025 is available in the table on this page.
What is Aytu BioPharma, Inc.'s net income?
Aytu BioPharma, Inc. (AYTU) trailing twelve-month net income is $-34M as of 2025. Earnings grew +24.5% year-over-year.
Is AYTU profitable?
AYTU is not currently profitable on a TTM basis, reporting a net loss of $-34M. Net margin is -20.4%. Investors should monitor for a return to profitability.
What is AYTU's earnings growth rate?
AYTU compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2007 to 2025.
What are AYTU's profit margins?
Aytu BioPharma, Inc. net profit margin is -20.4%, operating margin is -11.8%, and gross margin is +69.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -58.1%.
Is AYTU growing earnings?
Yes, AYTU earnings are accelerating — EPS growth of +24.5% exceeds the 5-year CAGR of N/A. TTM net income reached $-34M. Earnings momentum is strengthening.
What was AYTU's best earnings year?
Aytu BioPharma, Inc.'s highest annual net income on record is $-48954.00, achieved in fiscal year 2007. Earnings history on this page spans 2007 to 2025 and includes all annual and quarterly figures.
What were AYTU's earnings last quarter?
AYTU's most recent reported quarter was Q3 2026. Net income was $-6M with diluted EPS of $-0.53. For a full breakdown of all quarters, see the quarterly earnings table on this page.